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does not improve 6-month outcomes
Mark R. Nehler, MD,a Eric P. Brass, MD, PhD,b Richard Anthony, PhD,c John Dormandy, DSc,d
Jenny Jiao, PhD,c Thomas O. McNamara, MD,e and William R Hiatt, MD,a for the Circulase
investigators, Denver, Colo; Torrance, Pasadena, and Los Angeles, Calif; and London, United Kingdom
Purpose: In patients with critical limb ischemia (CLI), distal revascularization remains the procedure of choice for preventing
limb loss, but long-term outcomes for pain relief, wound healing, and prevention of amputation remain suboptimal.
Prostaglandin drug therapy as an adjuvant to revascularizationmay improve these outcomes. The current trial was designed to
test the hypothesis that the use of lipo-ecraprost, a lipid encapsulated prostaglandin E1 prodrug, as an adjunctive therapy after
distal revascularization would improve amputation-free survival in patients with CLI.
Methods: The study was randomized, multicenter, double blind, and placebo controlled. Patients meeting clinical and
hemodynamic criteria for CLI who were undergoing either bypass or endovascular revascularization of the below knee
popliteal or more distal arteries were randomized to receive placebo or a 60-g dose of lipo-ecraprost administered
intravenously starting<72 hours of the index revascularization and then 5 days per week for 8 weeks. The study primary end
point was the composite end point of death or amputation at or above the level of the ankle at 180 days.
Results: The study randomized 322 patients, and 284 received at least one dose of study medication and were included in the
intention-to-treat population. A total of 213 patients underwent surgical bypass, and 71 underwent endovascular revascular-
ization before receiving study medication. The distribution of index revascularization procedures and location of distal target
arteries were similar for both placebo and lipo-ecraprost groups. At 180 days, 21 patients (7.4%) were lost to follow-up before
reaching the primary end point. Seventy-one percent of the patients taking the placebo completed at least half the doses of the
study medication compared with 48% of those taking lipo-ecraprost. Index leg revascularization-assisted primary patency
was 82% in the placebo group and 84% in the lipo-ecraprost group (P .874). Changes in lower extremity hemodynamics
as a result of the revascularization during the study period did not differ between the placebo and lipo-ecraprost treatment
arms. For the primary event of amputation-free survival, there were no differences between groups: 19major amputations
occurred in the placebo group and 17 in the lipo-ecraprost group; 19 deaths occurred in the placebo group and 13 in the
lipo-ecraprost group.
Conclusion: Eight weeks of parenteral therapy with lipo-ecraprost after distal revascularization in patients with CLI
provided no additional benefit in the reduction of major amputation or death at 180 days. ( J Vasc Surg 2007;45:
953-61.)Peripheral arterial disease is the lower extremity mani-
festation of systemic atherosclerosis.1 Critical limb ischemia
(CLI) is manifest as ischemic pain at rest or ischemic ulcers
or gangrene, or both, and results when the blood flow
limitation becomes severe enough to compromise tissue
viability at rest.2 Current therapy for CLI is surgical or
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doi:10.1016/j.jvs.2006.12.057endovascular revascularization. However, despite advances
in revascularization techniques in the past two decades,
combined outcomes of amputation or death, or both, at 6
to 12 months are approximately 30%.3-5 In addition, sig-
nificant morbidity is incurred from revascularization proce-
dures, including prolonged wound healing and need for
secondary procedures.6,7 Ultimately, current revasculariza-
tion techniques only affect the pedal microcirculation by
improved inflow via the pedal and crural vessels.
The rationale for use of eicosanoids in CLI has been
previously discussed.8 In summary, prostaglandins vasodi-
late, promote angiogenesis, demonstrate antiplatelet activity,
and improve endothelial function in model systems and
patients.9-12 Each of these activities may be beneficial in
CLI. Major drawbacks of clinical therapy with prostaglan-
dins have been the short half-life (minutes) and hemody-
namic side effects of the compounds. Lipo-ecraprost is a
lipid encapsulation of the prostaglandin E1 analog ecra-
prost.13 Lipid encapsulation allows more rapid infusion of
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therapy, and may target the eicosanoid to the site of vascu-
lar injury.
Clinical trials of lipo-ecraprost in CLI patients without
revascularization options yielded primarily negative re-
sults.8 (Mitsubishi Pharma America, unpublished data,
2000). A major potential limitation of these trials was the
degree to which lipo-ecraprost could be delivered to the
pedal microcirculation owing to the severe uncorrected
obstructive arterial occlusive disease. Therefore, using lipo-
ecraprost as an adjunctive therapy to distal revascularization
to take advantage of the revascularization as conduit to
enhance drug delivery to the pedal microcirculation was
considered a potential improvement. The current trial
tested the hypothesis that 8 weeks of parenteral treatment
with lipo-ecraprost (60 g/day, 5 days/week) as an ad-
junctive therapy immediately after distal revascularization
would decrease the rate of major amputations or death at
180 days in patients with CLI.
MATERIALS AND METHODS
Overview of trial design. This was a multicenter,
randomized, double-blinded, placebo-controlled trial in
CLI patients after distal revascularization. The study was
sponsored by Mitsubishi Pharma America and was con-
ducted at 28 sites: nine were in theUnited Kingdom and 19
were in the United States (see “Principle Investigators”).
The target population was patients with atherosclerotic
CLI undergoing distal revascularization, which was defined
as a below knee popliteal or infrapopliteal artery as the
target for either distal anastomosis or endovascular therapy.
Patients were randomized, with stratification by dia-
betic status within each study site (conducted at a single
randomization center via a voice response system [Clin-
phone, Inc, East Windsor, NJ] and using a modified
Zelen’s approach14), to receive placebo or lipo-ecraprost
(60 g of ecraprost) administered intravenously72 hours
of the index revascularization procedure and then on each
of 5 days per week for a total of 8 weeks (maximum, 40 total
doses). The 60-g dose of ecraprost was chosen on the
basis of results of dose-ranging earlier phase studies. The
study was approved by the appropriate Institutional Review
Boards, and all patients provided informed consent.
Patient inclusion and exclusion criteria. Patients
were eligible for randomization if they were 40 years,
were able to provide informed consent (directly or through
an authorized representative), and had CLI clinically de-
fined by the presence of distal extremity pain at rest requir-
ing use of analgesics for at least 2 weeks or the presence of
peripheral ischemic ulcers or areas of gangrene. In addition,
they had hemodynamic evidence of CLI, which for patients
with rest pain (Fontaine stage III) required the highest
ankle systolic pressure (posterior tibial or dorsalis pedis) to
be 50 mm Hg in the affected limb, or the toe systolic
pressure to be 30 mm Hg, or a pedal transcutaneous
oxygen pressure (TcpO2) 30 mm Hg. In patients with
ischemic ulcers or gangrene (Fontaine stage IV), the ankle
and toe pressure and TcpO2 cutoffs in the affected limbwere 70 mm Hg, 50 mm Hg, and 30 mm Hg,
respectively.
For purposes of these analyses, clinical stage was deter-
mined from the index limb that was used for inclusion or
exclusion assessment. For example, if the index limb had
rest pain and qualifying hemodynamics, whereas the con-
tralateral limb had an ulcer but nonqualifying hemodynam-
ics, the patient was considered to have rest pain due to the
uncertain origin of the ulcer. Patients were also required to
be scheduled for a distal revascularization procedure (pa-
tients undergoing treatment of more proximal lesions in
conjunction with the distal procedure were eligible).
Patients were excluded from participation if they had a
previous major contralateral amputation (at or above the
level of the ankle) or if the area of an individual ulcer/
gangrene on the index limb was 20 cm2. Patients were
ineligible if they were on antihypertensive therapy that had
been changed within the previous 4 weeks or if they had
persistent or recurrent systolic blood pressure measure-
ments of90mmHg. Excluded were patients with clinical
evidence of sepsis, end stage renal disease (creatinine clear-
ance 20 mL/min), symptomatic arrhythmias, advanced
atrioventricular block, severe heart failure (New YorkHeart
Association class III or IV), or who had sustained a myo-
cardial infarction 12 weeks of treatment initiation. Pa-
tients were ineligible if at screening serum aspartate amino-
transferase or alanine aminotransferase exceeded three
times the upper limit of normal, or if serum bilirubin
concentration exceeded 1.5 times the upper limit of nor-
mal. Patients were excluded if they had received another
investigational drug of any type or had received prostanoid
therapy for peripheral arterial disease90 days of random-
ization. Women were eligible to participate only if they had
been surgically sterilized, were at1 year postmenopausal,
or had been practicing adequate contraception for at 12
weeks before entering the study.
An investigator could categorize a patient as ineligible
if, in the investigator’s opinion, the patient had a comorbid
condition likely to interfere with the end point assessment
or that compromised the patient’s safe participation in the
study, or if the patient was thought to be unreliable or
uncooperative.
Outline of study procedures. After providing in-
formed consent, patients underwent a series of screening
procedures that were completed10 days before random-
ization and distal revascularization. Screening included a
medical history, physical examination, electrocardiogram,
history of previous peripheral vascular interventions (revas-
cularizations and amputations), clinical and hemodynamic
assessment of the symptomatic lower extremity, and rou-
tine laboratory tests.
Patients whomet inclusion/exclusion criteria were ran-
domized before the distal revascularization procedure to
prevent biased enrollment based on outcomes of the pro-
cedures. This sequence meant that some patients random-
ized would not receive study medication, and thus not be
included in the study population, if their clinical status
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dural period.
Within 72 hours postprocedure, patients received their
first dose of study drug. The study medication was admin-
istered intravenously over approximately 10 minutes, and
the patient’s blood pressure and pulse were monitored.
Patients continued to receive the study medication 5 days
per week for 8 weeks. Adverse events were documented on
each dosing day, and on day 5, an additional electrocardio-
gram was performed 45 minutes after study medication
dosing.
Revascularization patency was determined by the site
investigator by imaging documentation (contrast arteriog-
raphy, magnetic resonance angiography, color flow Duplex
scanning) or by an increase in a preprocedural ankle-brachial
index of0.15. All patients had a patency assessment24
hours of the baseline revascularization to define technical
success.
At the 8-week time point, patients underwent a physical
exam, repeat assessment of the index limb (clinical assess-
ment and hemodynamic measurements and imaging to
determine revascularization patency using the same modal-
ities described to determine initial success), blood chemis-
try and hematology assessments, and an electrocardiogram.
Details of any amputation or revascularization procedures
were documented.
Patients were monitored by monthly phone contact
after the 8-week visit through 1 year, and information
concerning amputation or revascularization procedures
was obtained. Six months and 12 months after the first
study dose, the patients returned to the clinic and the
procedures conducted at week 8 were repeated.
Study end points and statistical considerations.
The primary efficacy end point was the proportion of
patients who underwent a major amputation at or above
the ankle or who died 180 days of the initial study
treatment. The anticipated event rate in the placebo group
was 30% as derived from literature data,3-5 which was
estimated to be one third deaths and two thirds amputa-
tions, or absolute rates of 10% and 20%, respectively. The
study was powered to detect a 75% reduction in amputa-
tions owing to lipo-ecraprost, assuming the drug had no
effect on mortality. It was thought that a decrease of this
magnitude would unambiguously establish a clinically
meaningful benefit. Thus, the projected active treatment
6-month event rate was 10% mortality and 5% amputation,
resulting in a 15% for the composite. Based on an   0.05
and a power of 80%, the study was designed to include 140
patients per arm, or a total of 280 treated subjects. The
expected dropout rate during the trial was 10%.
Analysis of the primary end point was by logistic regres-
sion assessing the effect of treatment on the primary event
rate with patients lost to follow-up considered treatment
failures and when adjusted for diabetic status and clinical
stage. Secondary analyses of the primary efficacy end point
included time-to-event using the Kaplan-Meier method,
Cox regression models, and analysis stratified by country
(United States vs United Kingdom).Additional secondary end points included 6-month
individual components of the primary end point, the num-
ber of cardiovascular adverse events, and assisted primary
patency of the index distal revascularization as defined by
the vascular surgery reporting standards.15 Additional sec-
ondary end points included patients who had complete
ulcer healing, resolution of pain at rest (assessed by patient
response to site investigator question), and change in index
limb hemodynamics.
For assisted patency assessment, all patients without
complete qualifying assessments (including deaths) were
censured from life-table analysis at the time of the last
qualifying assessment. In addition, owing to the location of
the initial revascularization, all patients with amputations
performed on the same leg where the index operation was
done were considered occluded at the time of amputation if
not noted to be occluded prior. Adverse events were com-
piled on a descriptive basis.
A protocol amendment approved by the Steering Com-
mittee resulted in the study being terminated after the final
patient completed the 6-month assessment. This was done to
expedite analysis of the primary end point and priority second-
ary end point using the 6-month data, as well as to minimize
study costs and research subject inconvenience. As a result,
although 6-month datawere obtained for all available subjects
excluding those lost to follow-up (see “Results”), only 146 of
the subjects completed a 12-month visit.
Other study design elements. Oversight of the study
was provided by three committees. The Steering Commit-
tee directed the protocol design, reviewed the study
progress and the statistical analysis plan, and prepared the
publications (the right to publish was a component of the
Steering Committee charter).
An independent Data and Safety Monitoring Board
(DSMB) met quarterly to review study progress and ad-
verse events in an unblinded manner. The DSMB also
conducted a protocol-specified interim analysis after 36% of
the planned total number of patients had completed the
6-month assessment. The interim analysis included a guide-
line that would support a recommendation for early termi-
nation if the conditional probability for a positive study,
based on the primary end point, was 0.20. The stopping
guidelines also included possible termination for benefit or
harm with an   0.00005, resulting in an adjusted  of
0.0499 for final analysis.
An independent Clinical Events Committee (CEC)
reviewed all adverse and serious adverse events. Based on
their review, the CEC categorized events as cardiovascular
when angina, congestive heart failure, myocardial infarc-
tion, stroke, transient ischemia, or acute limb ischemia was
determined to be the basis of the adverse event by using
prospective consensus criteria. The CEC also reviewed all
amputations and deaths to confirm the accuracy of re-
corded data and compliance with endpoint definitions.
RESULTS
The study took 51 months to complete (Aug 17, 2001
to Nov 14, 2005). A total of 322 patients were random-
ge.
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medication and thus comprised the intention-to-treat pop-
ulation. Thirty-eight patients were randomized before re-
vascularization but were not treated owing to a variety of
reasons, most commonly a change in medical status. Twenty-
eight sites enrolled at least one patient, with 70% of the
patients enrolled at one third of the sites.
The placebo and lipo-ecraprost treated groups did not
differ with respect to baseline characteristics (Table I).
Approximately 50% of the patients had diabetes, and 75%
presented with ischemic ulcers. The distribution of the
hemodynamic assessment of the qualifying lower extremity
was consistent with the diagnosis of CLI (Table II). In
patients with rest pain, 62% were enrolled after meeting
ABI criteria, with the remainder requiring either a toe
pressure or TcPO2 measurement to meet hemodynamic
inclusion criteria. In patients with ischemic ulcers, 56%
were entered based on ABI. Thus, a considerable number
of diabetic patients did not meet the ABI inclusion criteria
and were enrolled on the other hemodynamic parameters.
The distribution of index revascularization procedures
and location of distal target arteries was similar for both
placebo and lipo-ecraprost groups (Table III). Technical
success of the index revascularization in the immediate
postoperative period was achieved in 98% of the placebo
and lipo-ecraprost groups. The mean time from the revas-
cularization procedure until initial dose of study medica-
tion was similar between groups: 28 hours in the placebo
group and 26 hours in the lipo-ecraprost groups. The initial
dose of study medication was delayed24 hours in 28% of
placebo patients and in 24% of patients in the lipo-ecraprost
group. However, the lipo-ecraprost group had significantly
less adherence to the study medication over time: only 26%
received at least 35 doses of study medication compared
Table I. Patient demographics (intention-to-treat populat
Demographic* Placebo n (%)
Patients (n) 143
Age, mean years (range) 73 (40-93
Gender, M/F (% male) 104/39 (73)
Race
White 114 (80)
Black 12 (8)
Hispanic 10 (7)
Asian 4 (3)
Other/unknown 3 (2)
Diabetic 74 (52)
Hypertension 107 (75)
Prior MI 86 (26)
Prior CABG 23 (16)
Antiplatelet 120 (84)
Smoking
Current 36 (25)
Former 67 (47)
Fontaine stage III/IV (% IV)† 37/106 (74)
MI, Myocardial infarction; CABG, coronary artery bypass graft.
*Categoric data are presented as number (%), continuous data as mean, ran
†Fontaine stage III is rest pain; Fontaine stage IV is ischemic ulceration.with 51% assigned to the placebo group (Fig 1).At 6 months, eight patients in the placebo group and
13 in the lipo-ecraprost group were unavailable for the
primary end-point assessment. Lipo-ecraprost did not sig-
nificantly modify the prespecified primary end points of
death or major amputation when patients lost to follow-up
were considered as treatment failures in the logistic regres-
sion analysis adjusted for diabetic status and clinical stage
(P  .556). A major amputation occurred 6 months in
13% of the placebo-treated patients (19/143) and in 12% of
the patients (17/141) receiving lipo-ecraprost (Table IV). All
Lipo-ecraprost n (%) All
141 284
71 (47-90) 72 (40-93)
95/46 (67) 199/85 (70)
110 (78) 224 (79)
13 (9) 25 (9)
15 (11) 25 (9)
3 (2) 7 (2)
0 3 (1)
74 (53) 148 (52)
106 (75) 213 (75)
37 (26) 123 (26)
23 (16) 46 (16)
111 (79) 231 (80)
34 (24) 71 (25)
66 (47) 133 (47)
36/105 (75) 73/211 (74)
Table II. Distribution of hemodynamic measurements
by entry criteria grouped by Fontaine stage
Qualifying criteria for
study entry
Placebo
n (%)
Lipo-ecraprost
n (%)
Total
n (%)
Patients (n) 143 141 284
Fontaine stage III 37 36 73
Ankle pressure 50
mm Hg 24 (65) 21 (58) 45 (62)
Toe pressure 30
mm Hg 11 (30) 12 (33) 23 (31.5)
TcPO2 30 mm Hg 2 (5) 2 (6) 4 (5.5)
None of the above* 0 1 (3) 1 (1)
Fontaine stage IV 106 105 211
Ankle pressure 70
mm Hg 59 (56) 59 (56) 18 (56)
Toe pressure 50
mm Hg 41 (39) 38 (36) 79 (37)
TcPO2 30 mm Hg 3 (3) 8 (8) 11 (5)
None of the above* 3 (3) 0 3 (1)
TcPO2, Transcutaneous oxygen pressure.
*Enrolled as a protocol violation (suprasystolic ankle pressures, no toes
available for toe pressure assessment, and flat metatarsal pulse volume
recordings).ion)
)amputations were assessed by the CEC as secondary to
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trolled pain as the most common indications.
An analysis only of patients who received20 doses of
study medication supported the conclusion that lipo-
ecraprost did not affect amputation rates (data not shown).
Similarly, results from stratified analyses of prior minor
amputation, clinical stage, diabetic status, age73 years, or
study country (United States vs United Kingdom) did not
suggest a beneficial effect of lipo-ecraprost in any cohort
(data not shown).
Mortality during the 6-month study period was 13% in
the placebo group and 9% in the lipo-ecraprost group
(Table IV; P  .279). Mortality was not significantly re-
lated to clinical stage (11% rest pain vs 14% ischemic ulcers
in the placebo group, and 7% rest pain vs 10% ischemic
ulcers in the lipo-ecraprost group, based on the full
intention-to-treat cohort, P  .279). These data yielded
mean  standard error of the mean 6-month amputation-
Table III. Baseline index revascularization procedure
Placebo
n (%)
Lipo-ecraprost
n (%)
Total
n (%)
Surgical bypass 102 (71) 111 (79) 213 (75)
Endovascular 41 (29) 30 (21) 71 (25)
Distal target
BK popliteal 45 (31) 48 (34) 93 (33)
Tibial 94 (66) 84 (60) 178 (63)
Pedal 3 (2) 7 (5) 10 (3)
Unknown/violation 1 (1) 2 (1) 3 (1)
Conduit (bypass only)
Vein 85 (84) 99 (89) 184 (87)
Prosthetic 14 (14) 9 (8) 23 (11)
Composite 2 (2) 3 (3) 5 (2)
BK, Below knee.
Fig 1. Histogram of total received doses in lipo-ecraprost and
placebo groups. The numbers at the top of each pair of bars
represent the number of patients in the placebo and lipo-ecraprost
groups who completed doses of study drug in the range described
on the X axis.free survival rates of 0.74  0.04 in the placebo group and0.80  0.04 in the lipo-ecraprost group. Kaplan-Meier anal-
ysis confirmed the lack of treatment effect on amputation-free
survival (Fig 2).
Table V presents the 6-month changes in baseline
hemodynamics and assisted primary patency data. No sig-
nificant difference was found in 6-month hemodynamic
changes in available patients from baseline in the placebo
group compared with the lipo-ecraprost group. Primary
patency was not different at 6 months in the placebo group
(73%) compared with the lipo-ecraprost group (79%; P 
.967). Assisted primary patency was also not different at 6
months in the placebo group (82%) compared with the
Table IV. Major amputation and death within 180 days
in the intention-to-treat population
Event (%)
Placebo
n (%)
Lipo-ecraprost
n (%)
Patient, n 143 141
Major amputation 19 (13) 17 (12)
Death 19 (13) 13 (9)
Withdrawal without events
day 180 8 (6) 13 (9)
Composite all* 45 (32) 40 (28)
Composite Fontaine III 8/37 (22) 8/36 (22)
Composite Fontaine IV 37/106 (35) 32/105 (30)
Major amputation
Bypass 14/102 (14) 12/111 (11)
Endovascular 5/41 (12) 5/30 (17)
*Amputation or death, early dropouts without events are counted as failures.
In assessing the composite end point, each patient could only be counted
once. Therefore, because some patients had multiple qualifying end points
(major amputation and death or lost to follow-up), the sum of patients in
each event group could be greater than the total sum of patients with
composite end point.
Fig 2. Kaplan-Meier survival analysis for time to the first major
amputation or death in the intention-to-treat population. Patients
were censored from the analysis at the time of their last study
contact if they were lost to follow-up before the assessment at
month 6. The number of patients remaining in the placebo and
lipo-ecraprost cohorts, respectively, were 143 and 141 on day 1,
116 and 119 on day 60, 109 and 108 on day 120, and 97 and 101
on day 180.lipo-ecraprost group (84%). The lack of lipo-ecraprost
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procedure performed (Table V).
In patients with rest pain on entry, including those with
rest pain and ischemic ulcers, 34% of the placebo group and
32% lipo-ecraprost group were completely pain-free after 6
months (Table VI). For patients with ulcerations or gan-
grene on entry, 34% of the placebo group and 31% of the
lipo-ecraprost group were ulcer-free (all wounds 100%
healed/epithelialized) at 6 months (Table VI). In these
analyses, patients who underwent amputation or died were
considered treatment failures (ie, were not pain-free or
ulcer-free).
Adverse events were common in the study and consis-
tent with a population with severe vascular disease, the
morbidity of distal revascularizations, the use of intrave-
nous study drug administration, and the vasoactive charac-
teristics of lipo-ecraprost. Patients receiving lipo-ecraprost
experienced 2650 adverse events, of which 213 (8%) were
serious. The placebo group experienced 947 adverse
events, of which 218 (23%) were serious. Common nonse-
rious adverse events in the lipo-ecraprost group included
headache, pain, hypotension, tachycardia, vasodilation, di-
arrhea, nausea, and vomiting, all of which were usually
assessed as mild in severity by the investigator. Partly be-
cause of the higher frequency of adverse events in patients
in the lipo-ecraprost treatment arm, these patients were less
likely to complete their regimen compared with placebo
Table V. Changes in baseline entry hemodynamics and
assisted primary patency at six months.
Change in baseline
entry hemodynamics
at 6 months
Placebo,
n (%)
Lipo-ecraprost,
n (%) Total P
Surgical bypass
Improved* 47 (67) 48 (61) 95 (64)
No change† 19 (27) 23 (29) 42 (28)
Reduced‡ 4 (6) 8 (10) 12 (8)
Total 70 79 149
Endovascular
Improved* 24 (73) 16 (64) 40 (69)
No change† 8 (24) 8 (32) 16 (28)
Reduced‡ 1 (3) 1 (4) 2 (3)
Total 38 25 58
Patency at 6 months§
Assisted primary 82% 84% .885¶
Primary 73% 79% .914¶
Note: This analysis of hemodynamic outcomes excluded patients who
had occluded vessels (pressure 0) at baseline. A last observation carried
forward method was used for missing data, including those who died or
had amputations. The analysis is different than the life-table analysis of
assisted and primary revascularization patency, where patients who died
or did not have adequate assessments over time were censured at the time
of last valid data. This explains the apparent differences in hemodynamic
improvement and patency in the table.
*15% improvement from baseline.
†15% improvement or reduction from baseline.
‡15% reduction from baseline.
§Patency assessments were based on objective measures (ankle brachial
index, toe brachial index, duplex, or arteriography).
¶Calculated by 2 test; based on log-rank test of life-table method.patients (see above).The CEC identified 14 nonfatal cardiovascular adverse
events, including myocardial infarction, congestive heart
failure, and stroke, in the placebo group and 16 in the
lipo-ecraprost group at 6months. The CEC categorized 12
of the deaths (63%) in the placebo group and eight of the
deaths (62%) in the lipo-ecraprost arm at 6 months as
cardiovascular in nature.
DISCUSSION
The current trial demonstrated no efficacy for paren-
teral lipo-ecraprost as adjunctive therapy in patients under-
going distal revascularization for CLI. No difference was
found in the primary end point of amputation-free survival
at 6 months in the two groups. Secondary end points,
including ulcer healing, assisted primary patency, and free-
dom from pain, were also not different between groups at 6
months. The groups were well matched in demographics,
medical and vascular risk factors, and index revasculariza-
tion. The follow-up was excellent for a CLI trial, with
94% of the patients completing a 6-month assessment for
outcomes.
There were several limitations of the current trial of
lipo-ecraprost as adjunctive therapy for CLI. The protocol
predicted an overall event rate of the primary end point of
30% major amputation or death, which was approximated
in the study; however, the major amputation rate in the
placebo arm was only 13% (compared with the predicted
20%). As a result, the trial may have been underpowered
and a numerically small benefit of lipo-ecraprost on ampu-
tation cannot be excluded. Further, the study was powered
to detect a 75% reduction in amputations and thus was
underpowered to detect smaller possible effect sizes. For
example, the sample size required for detecting a difference
of 27.4% (placebo) vs 21.1% (lipo-ecraprost) in 6-month
event rates of major amputation or death would be 757
patients per group for 80% power and 1003 per group for
90% power (for two-sided test with an  level of 0.05).
Nonetheless, the absolute differences in amputation rates
observed in the current trial make a clinically meaningful
Table VI. Pain relief and ulcer healing at 6 months
Placebo, n (%) Lipo-ecraprost, n (%)
Pain on entry
Number 139 131
Pain free 48 (34) 41 (32)
Ulcer on entry
Number 106 105
Ulcer free 36 (34) 32 (30.5)
Note: Patients with rest pain on entry, regardless of Fontaine stage, were
reassessed for pain after 6 months. Patients were asked to characterize their
status at rest as having no leg pain, pain in the left leg, pain in the right leg,
or pain in both legs. Patients with ulcers on entry (Fontaine stage IV) were
assessed to determine if they were ulcer free (all wounds completely healed)
after 6 months. In both cohorts, patients who had died, undergone major
amputation, or who were lost to follow-up were considered as having
residual disease (that is, not pain or ulcer free).benefit of 60 g of lipo-ecraprost unlikely.
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 5 Nehler et al 959The current trial selected the 60-g dose of lipo-
ecraprost because previous work had suggested it was the
maximally tolerated dose in aged subjects. The phase II trial
had suggested efficacy at a 10-g dose, so it was anticipated
that the 60-g dose would have equal or greater efficacy. It
may have been too high for the postoperative CLI popula-
tion, however. The adherence to the protocol-specified
8-week study drug regimen was poor in the current trial of
post-revascularization CLI patients compared with trials of
parenteral lipo-ecraprost in CLI patients without revascu-
larization options (unpublished data, Mitsubishi Pharma
Corp).8 Patients with CLI who realize they have had an
initially successful revascularization (98% in the trial) may
be less likely to tolerate adverse events than CLI patients
who have no other viable treatment options. In addition,
patients recovering from the morbidity of a revasculariza-
tion procedure may be less tolerant of additional pharma-
cologic morbidity.
Compliance is a reported issue in the post revascular-
ization CLI population: an important cause of graft occlu-
sion is patient refusal to participate in postoperative graft
surveillance.16 Investigators may have tried to infer treat-
ment group assignments based on patient adverse events.
This is unlikely to have affected the study’s major end
points owing to their objective and durable nature. Fur-
ther, inference of assignment to active treatment may have
encouraged investigators to continue the aggressive treat-
ment schedule, contrary to the high discontinuation rate
observed.
It is important to compare the current study results
with the recently reported Prevent III17 and Bypass versus
Angioplasty in Severe Ischaemia of the Leg (BASIL)5 mul-
ticenter randomized trials of revascularization in CLI. One-
year mortality was 15.8% in Prevent III and 6-month
mortality was 12.6% in BASIL, the latter comparable with
the current trial. The combined 6-month end point of
amputation/death was 21% in BASIL and limb salvage at 1
year was 88% to 89% in Prevent III, both figures not widely
different than the 6-month amputation rate of 13% in the
current trial. Finally, 1-year assisted primary patency in
Prevent III was 75% to 79% compared with 82% to 84% at
6 months in the current trial. These similarities suggest that
patients enrolled in the current trial are representative of
the CLI population as studied in other trials.
Although adverse cardiovascular events and cardiovas-
cular mortality were not statistically different between
groups in this trial, there was a trend towards increased
events in the lipo-ecraprost group at the 6 and 12 month
end points in the companion trial of lipo-ecraprost in
patients with CLI who had no revascularization options.8
In addition, secondary end points of patency, relief of rest
pain, and complete ulcer healing were not improved by
lipo-ecraprost, a finding consistent with the companion
trial.8 Finally, although cardiovascular events were no dif-
ferent in the two groups, the number of adverse events was
markedly greater in the lipo-ecraprost group, in part limit-
ing the cumulative drug exposure in that population.CONCLUSION
Parenteral lipo-ecraprost as an adjunctive therapy to
distal revascularization in patients with CLI demonstrated
no efficacy. The results of this trial were similar to the
results of the companion trial of lipo-ecraprost used as
primary therapy in CLI patients without revascularization
options.8 The current trial amputation-free survival results
are relatively comparable with other recently reported mul-
ticenter trials5,17 of distal revascularization in patients with
CLI, suggesting they are representative of the general
CLI population. The combination of high incidence of
adverse events, poor tolerability of the drug in the post-
revascularization CLI population, and lack of demon-
strated efficacy should discourage future use of aggressive
PGE-based therapies in this population.
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Dr Fred Weaver (Los Angeles, Calif). I would like to con-
gratulate Dr Nehler on a fine presentation and all the Circulase
investigators on a well designed and conducted clinical trial. The
objective of this trial was to examine the utility of lipo-ecraprost, a
prostaglandin analog, as an adjunct to lower extremity revascular-
ization in patients with chronic limb-threatening ischemia. Intra-
venous infusion of lipo-ecraprost or placebo control was com-
menced at 72 hours after revascularization and continued for 5
days per week for 8 weeks. The therapeutic groups were well
matched for degree of ischemia, type of revascularization required,
and comorbid conditions. Subsequent primary and assisted pri-
mary patency of revascularization procedures performed were sim-
ilar between placebo and the study drug groups.
Despite the fact that this trial did not show any advantage of
lipo-ecraprost over placebo in the primary end point of 6-month
amputation-free survival, there are a number of valuable findings in
this study that require comment. First, the complexity of designing
and conducting a trial in patients with chronic limb ischemia is
significant. Providing a stratification of risk and randomization that
provides for an apple-to-apple comparison requires significant
forethought and valid statistical methodology. In large part, the
trial accomplished this objective and is a model for future studies
on patients with chronic limb ischemia.
Second, the results of lower extremity revascularization docu-
mented in this trial for patients with limb-threatening ischemia are
sobering. At 6 months, either amputation or mortality had oc-
curred in 26% and 21% in the placebo and the study drug groups,
respectively. In addition to those clinical failures was a finding that
only a third of patients in both arms were rest-pain or ulcer-free atwere clinical failures at 6 months despite the presence of a success-
ful revascularization in over 80%.
Third, lipo-ecraprost was poorly tolerated, with less than 50%
of patients actually receiving the total number of infusions directed
by the protocol. The adverse event rate in the lipo-ecraprost arm
was very significant, with 2650 adverse events compared with only
947 in the placebo arm. Although I have not performed a statistical
analysis, it appears that this increase in the adverse event rate with
lipo-ecraprost is one important statistically significant finding of
this study.
I have a number of questions for Dr Nehler. Three hundred
thirteen patients were randomized but only 284 received the
randomized treatment. Why? What happened to the 29 patients
who were randomized but not treated? Your analysis was based on
an intent-to-treat strategy. My understanding is that once a patient
is randomized in intent-to-treat analyses, they are included in the
statistical analysis even if they did not receive the randomized
treatment. This was not the case in your analysis where these 29
randomized patients were excluded. Could you explain the statis-
tical rationale for the exclusion of these 29 patients?
Two, the initial power estimates for this study were predicated
on a combined amputation mortality rate of 30%, which becomes
significant given the negative findings of the study. In your paper,
you comment on this power calculation and then cite two other
prospective studies with a combined amputation mortality rate of
less than 25%. This raises the issue as to whether the current study
is underpowered. The statistical concern is further accentuated by
the fact that less than 50% of patients received all infusions of the
study drug. Consequently, are you and your fellow investigators
satisfied that the results reported today are valid and exclude a
JOURNAL OF VASCULAR SURGERY
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have underpowered the study?
Three, revascularization was performed using both open and
endovascular procedures. In your patency analysis, did you sepa-
rate the patency outcomes of open and endovascular procedures? If
so, what were the findings, and were there any significant differ-
ences between open and endovascular primary and primary assisted
patencies at 6 months?
Four, why was the lipo-ecraprost dose of 60 g used in this
study? As you mentioned in your discussion, salutary results have
been reported for a dose of 10 g in the chronic limb ischemia
patient. It would seem that if 10 g with uncorrected occlusive
disease is beneficial, then six times that dose in patients in whom
the occlusive disease has been surgically treated is overkill and
could lead to intolerance of the study drug, which was found in this
study. What was the reason for the 60-g dose chosen in this
study?
In conclusion, I congratulate Dr Nehler and his colleagues on
a well designed, albeit negative study, and I look forward to his
comments to the above questions. Thank you for your attention.
Dr Mark Nehler. Thanks, Dr Weaver, for those excellent
comments and questions. The first question was the intent-to-treat
group a protocol design where we wanted to include the patients
who had received at least one dose of the study material. In the
top-line analysis tables of the FCSR, we did look at all of the
patients and adding the excluded patients did not change the
conclusions. Patients who did not receive study material despite
randomization was due to change in clinical status following index
revascularization that precluded dosing within the required 72-
hour window.
With regards to the powering of the study, that is one of the
major criticisms. At the time that we did the design for this trial,
BASIL had not finished, PREVENT-III was not done, so there was
a relative dearth of level 1 data in critical limb ischemia patients. We
were using older historic controls to try to calculate what we
thought was going to be the 6-month event rates, some of them
which were actually earlier prostaglandin trials from Europe with
smaller numbers of patients. We did miscalculate.
Although I put the more recent trials in the discussion and in
the introduction, the event rates do not add up completely to our
calculations. We could have underpowered the study. One of the
worst things you can do in designing a clinical trial is to predict an
event rate that you do not achieve because obviously patients
without events cannot be modified by your agent, so it is much
better to predict an event rate that is lower than what you think you
are going to get and then get more events because you have amuch
better chance of having a positive trial. That is a valid criticism of
our design.Open vs endovascular-assisted patency rates were not com-
pared primarily because we had only a small number of endovas-
cular patients and adherence to the assisted protocol was poor,
with many patients censured from the life-table. We compared
amputations between the two groups and there was no difference.
The rationale for the study dose was brought up in the steering
committee when we discussed the results of this trial. At the time of
trial design, the agent efficacy was felt to be dose-related, and
unpublished results that showed some benefit at the highest toler-
able dose. The sponsor felt the reason that previous trials had been
mixed was because of inadequate dosage. In retrospect, the dosage
probably was too high, especially to be tolerated in this population.
Interestingly, the number of dropouts in the stand-alone trial just
published in JVS a few months ago is much less than the current
adjunctive trial. Patients with unreconstructable critical limb isch-
emia are willing to tolerate side effects and finish their course of
therapy, but revascularized patients are much less tolerant.
Of note, Mitsubishi Pharma has actually sold this agent to a
smaller company in Japan that is going to continue to market it.
This particular product is used a tremendous amount in China.
That is probably their number one worldwide usage right now.
The whole issue of prostaglandins has not really gone away
because there is a recent study out of theAnnals of Surgery from an
Italian group where they did a multicenter trial in acute limb
ischemia using iloprost both intra-arterially at the time of either
revascularization or thrombolysis as well as an adjunctive intrave-
nous infusion for a week postprocedurally, with a positive result.
They dropped their amputation mortality at 3 months from 20% in
the placebo group to 15% in the treatment group, so in Europe and
in other parts of the world prostaglandins still get used a tremen-
dous amount.
Dr Ted Kohler (Seattle, Wash). Very nice study, Mark. I
compliment your group for publishing negative results, which are
just as important as positive ones. I would not worry too much
about being underpowered. Underpowering is a problem for
potential type II errors, but this is usually when there is an observed
difference but the P value does not reach statistical significance due
to a lack of adequate sample size. In your case, there is no observed
difference between the two groups, so there is very little concern
that there may be a small difference, and if there were a difference,
it would not likely clinically significant.
Dr Nehler. That is an excellent point. Actually of the two
trials, probably the only thing that we were worried about being
underpowered for was the potential for adverse cardiac events in
the stand-alone trial where we did see a trend, but it was not
significant. I think much more crucial in this trial was the dosage.
